Gritstone Oncology, Inc. (GRTS)
| Market Cap | 1.05B |
| Revenue (ttm) | 3.57M |
| Net Income (ttm) | -105.85M |
| Shares Out | 37.75M |
| EPS (ttm) | -2.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $25.34 |
| Previous Close | $22.27 |
| Change ($) | 3.07 |
| Change (%) | 13.79% |
| Day's Open | 19.32 |
| Day's Range | 18.92 - 35.20 |
| Day's Volume | 37,453,274 |
| 52-Week Range | 2.57 - 35.20 |
Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.
— Deal provides nonexclusive access to Genevant's leading LNP technology for use in Gritstone's self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to i...
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-base...
Gritstone's COVID-19 vaccine may have a critical role to play in halting the ongoing pandemic.
--Gritstone to Host Conference Call Today at 8:00 a.m. ET-- EMERYVILLE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology compan...
--Received Gross Proceeds of $110 Million from Previously Announced PIPE Financing-- --Executed Additional PIPE Financing of $15 Million-- EMERYVILLE, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) --...
EMERYVILLE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies t...
Shareholders of 36KR Holdings Inc (NASDAQ:KRKR) and Gritstone Oncology Inc (NASDAQ:GRTS) have seen their holdings tumble more than 59% over the past 12 months, but analysts still recommend to ...
EMERYVILLE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies t...
-- The Phase 1 portion s of the stud ies are closed for enrollment ; patient trea tment and follow -up for efficacy and safety continues -- EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -...
EMERYVILLE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology , Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunothera...
EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapie...
It's Time To Buy Gritstone Oncology As First Vaccine Treated Colorectal Cancer Patient Nears RECIST Confirmed Response
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 10.39% and -59.33%, respectively, for the quarter ended June 2020.
EMERYVILLE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies...
Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
EMERYVILLE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to ...
Despite The Fall Gritstone Oncology Phase 1 Results Reveal The Efficacy Signal I've Been Looking For
Despite The Fall Gritstone Oncology Phase 1 Results Reveal The Efficacy Signal I've Been Looking For
For the most part, biotech and pharmaceutical companies are involved in the lengthy process of getting their drug candidates to market through clinical trials.
If there’s one thing that's been made more clear, it’s that the stock market and economy are not reflections of each other. An overbought stock market will eventually turn to the downside, and...
EMERYVILLE, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies...
Gritstone Oncology (GRTS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Gritstone Oncology Inc (GRTS) delivered earnings and revenue surprises of 14.46% and 5.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the...
EMERYVILLE, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies ...
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -1.32% and -26.33%, respectively, for the quarter ended December 2019.
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -13.24% and -18.00%, respectively, for the quarter ended September 2019.
Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
-Poster Presentation at SITC 2019 Annual Meeting-
EMERYVILLE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies...
EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to...
EMERYVILLE, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapie...
The pricing of a secondary stock offering is taking a toll on the biotech stock.
About GRTS
Gritstone Oncology, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, incl... [Read more...]
| Industry Biotechnology | IPO Date Sep 28, 2018 |
| CEO Andrew Allen | Employees 177 |
| Stock Exchange NASDAQ | Ticker Symbol GRTS |
Financial Performance
In 2019, GRTS's revenue was $4.37 million, an increase of 267.73% compared to the previous year's $1.19 million. Losses were -$94.43 million, 45.8% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for GRTS stock is "Buy." The 12-month stock price forecast is 11.25, which is a decrease of -55.60% from the latest price.